A prospective comparison of diabetic foot ulcers treated with either a cryopreserved skin allograft or a bioengineered skin substitute

Wounds

Volumn 23, Issue 7, 2011, Pages 184-189

  Didomenico, Lawrence ^a   Landsman, Arnold R ^a   Emch, Kenneth J ^b   Landsman, Adam ^b,c,d  

^a Ankle and Foot Centers   (United States)

^b Soluble Systems   (United States)

^c CAMBRIDGE HEALTH ALLIANCE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052758432     PISSN: 10447946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Sheehan P, Jones P, Giurini JM, Caselli A, Veves A. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Plast Reconstr Surg. 2006;117(7 Suppl):239S-244S. (Pubitemid 44317787)
2. Langer A, Rogowski W. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers. BMC Health Serv Res. 2009;10(9):115.
3. Landsman A, Roukis TS, DeFronzo DJ, Agnew P, Petranto RD, Surprenant S. Living cells or collagen matrix: which is more beneficial in the treatment of diabetic foot ulcers? WOUNDS. 2008;20(5):111-116.
4. Landsman AS, Cook J, Cook E, et al. A retrospective clinical study of 188 consecutive patients to examine the effectiveness of a biologically active cryopreserved human skin allograft (TheraSkin®) on the treatment of diabetic foot ulcers and venous leg ulcers. Foot Ankle Spec. 2011;4(1):29-41.
5. Landsman, et al. Head-to-head retrospective study of DermaGraft and TheraSkin for the treatment of complex wounds: preliminary report. Abstract presented at: The Symposium on Advanced Wound Care; Dallas, TX; April 14-17, 2011.
6. Veves A, Falanga V, Armstrong DG, Sabolinski ML. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. 2001;24(2):290-295. (Pubitemid 32119127)
7. Steinberg JS, Edmonds M, Hurley DP Jr, King WN. Confirmatory data from EU study supports Apligraf for the treatment of neuropathic diabetic foot ulcers. J Am Podiatr Med Assoc. 2010;100(1):73-77.